fda semaglutide warning september 2025 8, 2025: launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines FDA Issues Warnings Against Illegal

Combined, more than seven in ten American adults carry excess weight that elevates their risk for type 2 diabetes, cardiovascular disease, certain cancers, and a range of musculoskeletal disorders

Liver Fat Clinical trials demonstrate that retatrutide reduces liver fat content by up to 60% in certain cohorts over a 48-week period, particularly at elevated doses

Our latest research explores early dosing trends for oral semaglutide for obesity and found that providers are generally following the recommended schedule for dose increases, an important step in helping patients tolerate therapy and stay on treatment

Clear answers matter before anyone commits to a long-term weight-loss plan